AU2722600A - Inhibition of cd4-ccr5 interaction - Google Patents

Inhibition of cd4-ccr5 interaction

Info

Publication number
AU2722600A
AU2722600A AU27226/00A AU2722600A AU2722600A AU 2722600 A AU2722600 A AU 2722600A AU 27226/00 A AU27226/00 A AU 27226/00A AU 2722600 A AU2722600 A AU 2722600A AU 2722600 A AU2722600 A AU 2722600A
Authority
AU
Australia
Prior art keywords
inhibition
ccr5 interaction
ccr5
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27226/00A
Inventor
Dimiter S Dimitrov
Xiadong Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2722600A publication Critical patent/AU2722600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU27226/00A 1999-01-08 2000-01-06 Inhibition of cd4-ccr5 interaction Abandoned AU2722600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11518299P 1999-01-08 1999-01-08
US60115182 1999-01-08
PCT/US2000/000417 WO2000040964A1 (en) 1999-01-08 2000-01-06 Inhibition of cd4-ccr5 interaction

Publications (1)

Publication Number Publication Date
AU2722600A true AU2722600A (en) 2000-07-24

Family

ID=22359763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27226/00A Abandoned AU2722600A (en) 1999-01-08 2000-01-06 Inhibition of cd4-ccr5 interaction

Country Status (2)

Country Link
AU (1) AU2722600A (en)
WO (1) WO2000040964A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
CN1227610A (en) * 1996-06-03 1999-09-01 美国联合生物医学公司 Antibodies against a complex of CD4 and a chemokine receptor domain, and their use against HIV infections
CA2257991A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Also Published As

Publication number Publication date
WO2000040964A1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU6465400A (en) Inhibition of action potentials
AU5546000A (en) Compounds
AU3791601A (en) Treatment of coal
AU2557500A (en) Methods of making compounds
AU4343500A (en) Use of azetidinone compounds
AU6111000A (en) Inhibitors of viral helcase
AU2678800A (en) Modified calycins
AUPP999799A0 (en) New compound
AU1488501A (en) Methods of inhibiting metastasis
AUPQ137699A0 (en) Control of acidosis
AU6564600A (en) Copolymers of acryloyloxyalkylamino compounds
AU1746401A (en) Compounds
AU6032100A (en) New compounds
AU6690300A (en) Copolymers of acryloylaminoalkyl compounds
AU3997700A (en) Anti-first-pass effect compounds
AU3235100A (en) Prothease inhibitors
AU4369000A (en) Inhibition of complement action
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU5433699A (en) Spacing of tiles
EP1218407A4 (en) Uses of kappa-conotoxin pviia
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
AU1389801A (en) Modification of plants
AU7711800A (en) Novel uses of 2-bromopalmitate
AU5787901A (en) Compound

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase